Affiliate disclosure: As an Amazon Associate, AgmatineHub earns from qualifying purchases. This helps support our research and content creation, and it does not affect what we recommend. Full disclosure.
- The side effect human studies keep reporting is stomach upset: in the main dose-escalation trial, 3 people at the highest dose (3.56 g/day) had mild-to-moderate diarrhea and mild nausea that stopped when they stopped taking it[1], and two small independent case series saw the same kind of mild, passing GI symptoms[7][8]
- Low blood pressure is an animal-study caution, not an observed clinical effect; in animals agmatine has pushed blood pressure up or down depending on dose and route[4]
- The only placebo-controlled trial and the long-term safety report share one author, whose company holds a commercial stake in the ingredient tested; independent human data covers 8 people across two small case series[1][2][7][8]
- The widely repeated “five years with no side effects” figure comes from two researchers monitoring themselves, not from a trial[2]
Agmatine is popular in nootropic and bodybuilding circles for its claimed effects on mood, pain and training. Look for what goes wrong with it and the clinical record turns up very little reported harm. The real weakness is how small that record is and how much of it comes from a single source, which matters more to a buyer than any one side effect.
What the Human Trials Actually Report
The most detailed safety data comes from a 2010 study in people with nerve pain from a herniated lumbar disc[1]. It opened with a dose-escalation phase: groups took 1.335 g/day, 2.67 g/day or 3.56 g/day of agmatine sulfate for 10 days, and a final group took 3.56 g/day for 21 days. Safety measures stayed within normal values for everyone. Three participants in the highest-dose group had mild-to-moderate diarrhea and mild nausea, which went away once treatment stopped, and no other events were observed[1].
The second phase was a randomized, double-blind, placebo-controlled trial at 2.67 g/day for 14 days. 51 people were assigned to agmatine and 48 to placebo, and no treatment-related adverse events were noted[1]. One thing to keep in mind when reading the efficacy numbers: only 31 and 30 participants were analyzed, so roughly a third of the people enrolled are not in the final results.
Notice what is missing from that list. Dizziness and low blood pressure are repeated in many supplement write-ups, but neither was observed in this trial. The blood-pressure concern comes from animal research: a 2025 systematic review of 60 studies, almost all preclinical, found agmatine can move blood pressure and heart rate in either direction depending on the dose, the route it is given by and the receptors involved[4]. That is a reason for care if you already take blood-pressure medication. It is not evidence that users commonly feel lightheaded.
The Bigger Complaint: One Research Group Produced Most of the Human Data
A PubMed search for human studies of agmatine supplementation turns up five. Three of them, including the only placebo-controlled trial, share an author: the 2010 disc trial[1], a 2014 case report[2], and a 2020 open-label series in which 11 people with painful small fiber neuropathy took 2.67 g/day for two months[3]. Gad M. Gilad is an author on all three. The 2020 paper discloses that he co-owns patents on products related to the work and holds stock in Gilad&Gilad LLC, and the capsules tested used that company’s G-Agmatine brand of agmatine sulfate[3]. The 2024 lab study that found no mutagenic or genotoxic effects tested the same proprietary ingredient, with the same declared interests[5].
None of this makes the results wrong. Industry-linked research is common and these studies went through peer review. It does mean the independent human data is very thin: a 2013 pilot report on 3 people with major depression[7] and a 2026 open-label case series of 5 adults with treatment-resistant OCD who took 650 mg rising to 1300 mg a day[8]. Both describe agmatine as well tolerated, with mild gastrointestinal symptoms in one and two patients respectively, but neither had a placebo group, and neither did the 2020 study[3]. A 2013 review written by 16 research groups summed up the field as substantial preclinical evidence plus initial clinical evidence[6], and that is still a fair description.
Drug Interaction Cautions
We found no formal human studies of agmatine drug interactions, so these cautions come mostly from how agmatine works. It acts on imidazoline receptors, alpha-2 adrenoceptors, NMDA receptors and serotonin receptors, and it was first identified as the body’s own “clonidine-displacing substance”[4]. Clonidine is a blood-pressure drug. If you take antihypertensives, or psychiatric medication that acts on serotonin, ask your prescriber before adding agmatine, because that receptor overlap is a plausible route for the effects to stack. The one small piece of human evidence on SSRIs is reassuring but tiny: in the 2026 OCD series, all five patients took agmatine alongside stable SSRI doses and none stopped because of side effects[8]. Five people is too few to rule a problem out.
The “Five Years, No Side Effects” Claim
Agmatine is often described as safe at high doses over the long term. That claim traces back to a 2014 case report[2]. Its two authors, Gad and Varda Gilad, took 2.67 g/day of agmatine sulfate themselves, as six 445 mg capsules a day, for four to five years, with periodic physical exams and blood and urine tests. All measurements stayed within normal values[2].
That is a real data point, and more than many supplements have. But it is two people, unblinded, monitoring themselves, and connected to the company behind the ingredient. Read it as an encouraging anecdote, not proof of long-term safety. The longest placebo-controlled human exposure in the published record is 14 days[1], and the longest uncontrolled follow-up, in the OCD series, ran 112 days at up to 1300 mg a day, about half the dose in the case report[8].
What Is Still Unknown
The human studies enrolled adults with back or nerve pain, depression or OCD, plus the two authors of the case report[1][2][3][7][8]. There is no published data on people who are pregnant or breastfeeding, on teenagers, or on people with kidney or heart disease. If you are in one of those groups, there is no evidence either way to go on, which is a reason to talk to a doctor first rather than a reason to assume it is fine.
FAQ
Is agmatine FDA-approved?
No. Agmatine sulfate is sold as a dietary supplement and has not been approved as a drug for any condition. The human evidence so far is a handful of small studies[1][3].
What’s the most common agmatine side effect?
In the one dose-escalation trial, the only side effects reported were mild-to-moderate diarrhea and mild nausea in three people taking 3.56 g/day, the highest dose tested. Both went away when they stopped[1]. Two small independent case series also reported only mild, short-lived stomach symptoms[7][8].
Is agmatine safe with blood pressure medication?
Not without medical guidance. Agmatine acts on the same receptor family as the blood-pressure drug clonidine, and in animal studies it has shifted blood pressure in both directions[4]. There is no human data on combining it with blood-pressure drugs.
Is 2.67 g a day safe long term?
Nobody knows from controlled data. The only long-term evidence is the two-person self-report described above[2]; controlled human data at that dose covers 14 days[1].
References
- Keynan O et al. Safety and Efficacy of Dietary Agmatine Sulfate in Lumbar Disc-associated Radiculopathy. An Open-label, Dose-escalating Study Followed by a Randomized, Double-blind, Placebo-controlled Trial. Pain Medicine (2010). PMID 20447305
- Gilad GM, Gilad VH. Long-term (5 years), high daily dosage of dietary agmatine – evidence of safety: a case report. Journal of Medicinal Food (2014). PMID 25247837
- Rosenberg ML et al. Evidence for Dietary Agmatine Sulfate Effectiveness in Neuropathies Associated with Painful Small Fiber Neuropathy. A Pilot Open-Label Consecutive Case Series Study. Nutrients (2020). PMID 32102167
- Manole OM et al. Exploring the Cardiovascular Impacts of Agmatine: A Systematic Review. Medical Sciences (Basel) (2025). PMID 41283257
- Gilad VH et al. Evidence for safety of the dietary ingredient agmatine sulfate as assessed by mutagenicity and genotoxicity studies. Toxicology Reports (2024). PMID 39286406
- Piletz JE et al. Agmatine: clinical applications after 100 years in translation. Drug Discovery Today (2013). PMID 23769988
- Shopsin B. The clinical antidepressant effect of exogenous agmatine is not reversed by parachlorophenylalanine: a pilot study. Acta Neuropsychiatrica (2013). PMID 25287313
- Salvi JD. Agmatine augmentation in treatment-resistant obsessive-compulsive disorder: a prospective open-label case series. Frontiers in Psychiatry (2026). PMID 41717561
These statements have not been evaluated by the Food and Drug Administration. This information is not intended to diagnose, treat, cure, or prevent any disease. Content is for informational purposes only and is not medical advice; consult a qualified healthcare provider before starting any supplement. As an Amazon Associate we earn from qualifying purchases.
